Abstract: Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with phamarceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.
Type:
Grant
Filed:
January 26, 2015
Date of Patent:
September 20, 2016
Assignees:
WESTERN UNIVERSITY OF HEALTH SCIENCES, TESORX PHARMA, LLC
Inventors:
Guru V. Betageri, Ramachandran Thirucote, Veeran Gowda Kadajji
Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.
Abstract: The present disclosure relates to pharmaceutical compositions comprising omeprazole, lansoprazole and sodium bicarbonate. Methods of using such compositions are also provided.
Type:
Grant
Filed:
September 18, 2014
Date of Patent:
May 31, 2016
Assignee:
The Curators of the University of Missouri
Abstract: The present invention relates to a fast dissolving granulate formulation containing the veterinary drug azaperone and a method for preparing said granulate formulation.
Type:
Grant
Filed:
June 21, 2012
Date of Patent:
May 17, 2016
Assignee:
Elanco Animal Health Ireland Limited
Inventors:
Dieter Bert Leen Ameye, Lieven Van Vooren, Peter Meerts, Geert Louise F. Van Beeck, Raja Satyanarayana Yekkala
Abstract: Disclosed is the use of 5?-androstane-3?,5,6?-triol in preparing neuroprotective drugs. The compound has significant protective effect against neuron injuries caused by cerebral ischemia, spinal cord ischemia or hypoxia and has no obvious toxic reaction within effective dose thereof.
Abstract: The invention relates to a pharmaceutical product comprising a dibenzofuranone derivative as the active ingredient. The invention further relates to the use of dibenzofuranone derivatives to inhibit kinases, in particular serine/threonine kinases, to the use of dibenzofuranone derivatives for producing drugs and/or medicinal products for treatment, and to the use of dibenzofuranone derivatives as a diagnostic product for analyzing the role of protein kinases, in particular serine/threonine kinases, in particular protein kinase CK2 in cellular processes, the pathogenesis of diseases, ontogenesis and/or other developmental biological phenomena or relationships.
Type:
Grant
Filed:
June 22, 2011
Date of Patent:
April 5, 2016
Inventors:
Joachim Jose, Claudia Götz, Andreas Gratz, Uwe Kuckländer
Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-(4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.
Type:
Grant
Filed:
March 2, 2015
Date of Patent:
March 15, 2016
Assignees:
LABORATOIRE HRA-PHARMA, The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Andre Ulmann, Erin Gainer, Henri Camille Mathe, Diana Blithe, Lynnette Nieman
Abstract: A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.
Type:
Grant
Filed:
January 6, 2014
Date of Patent:
February 9, 2016
Assignee:
GALAPAGOS NV
Inventors:
Frédéric Gilbert Labéguère, Gregory John Robert Newsome, Luke Jonathan Alvey, Laurent Raymond Maurice Sanière, Stephen Robert Fletcher
Abstract: The present invention is directed to a method of preventing or treating a gastrointestinal condition in a subject, that includes administering one or more branched chain fatty acid to the subject under conditions effective to prevent or treat the gastrointestinal condition in the subject. In general, branched chain fatty acids, in accordance with the present invention, may be non-esterified fatty acids or covalently linked to a lipid, including wax esters, sterol esters, triacylglycerols, or any other lipid-related molecular species, natural or artificial. The branched chain fatty acid can be a C11 to C26 branched chain fatty acid and mixtures thereof.
Abstract: Compounds, pharmaceutical compositions and methods for treating viral and bacterial infections, by administering certain thiourea compounds, specifically acylthiourea, carboximidoylthiourea and S-alkyl isothiourea derivatives and analogs, in therapeutically effective amounts are disclosed.
Type:
Grant
Filed:
February 18, 2011
Date of Patent:
January 12, 2016
Assignee:
SIGA TECHNOLOGIES, INC
Inventors:
Robert D. Allen, Sean M. Amberg, Dongcheng Dai, James R. Burgeson, Dennis E. Hruby
Abstract: The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity.
Type:
Grant
Filed:
March 8, 2013
Date of Patent:
December 22, 2015
Assignees:
BAGI RESEARCH LIMITED, VERSITECH LIMITED
Inventors:
Allan Sik Yin Lau, Lai Hung Cindy Yang, Stanley Chi Chung Chik
Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
Type:
Grant
Filed:
November 2, 2012
Date of Patent:
December 15, 2015
Assignee:
Theravance Biopharma R&D IP, LLC
Inventors:
Daniel D. Long, Robert Murray McKinnell, Lan Jiang, Mandy Loo, Kassandra Lepack, Lori Jean Van Orden, Gavin Ogawa
Abstract: The present invention identifies a compound which binds to the PAH1 domain of mSin3B that specifically binds to neural restrictive silencer factor NRSF, and uses the compound as a prophylactic and/or a therapeutic for diseases associated with abnormal expression of neural restrictive silencer factor NRSF/REST or abnormal expression of genes targeted by NRSF/REST, such as Huntington's disease, medulloblastoma and neuropathic pain. The present invention provides a pharmaceutical composition comprising a substance capable of binding to the PAH1 domain of mSin3B, e.g.
Type:
Grant
Filed:
February 9, 2011
Date of Patent:
December 8, 2015
Assignees:
PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, NAGASAKI UNIVERSITY, NAGOYA CITY UNIVERSITY
Abstract: Provided herein are analog and derivative compounds of inositol hexakisphosphate effective to treat a Clostridium difficile infection and to neutralize the bacterial toxins produced by the same. In addition, methods of treating the C. difficile infection and for neutralizing its toxins with the compounds are provided.
Type:
Grant
Filed:
October 14, 2013
Date of Patent:
December 1, 2015
Assignee:
The Board of Regents of the University of Texas Systems
Inventors:
Tor C. Savidge, Petril Urvil, Dhananjaya Nauduri, Numan Oezguen, Catherine Schein, Werner Braun
Abstract: Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, methods for using the chrysophaentin compounds, and methods for synthesizing the chrysophaentin compounds are disclosed. Certain embodiments of the chrysophaentin compounds inhibit FtsZ protein, thereby inhibiting the growth of clinically relevant bacteria, including drug-resistant strains.
Type:
Grant
Filed:
February 24, 2012
Date of Patent:
October 27, 2015
Assignees:
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Abstract: The present invention is directed to the following compound: The compound is associated with activity of a muscarinic receptor (e.g., one or more of M1, M2, M3, M4, M5).
Abstract: The present invention provides ?-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.
Abstract: Benzimidazole, benzopyrazole and benzotriazole compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.
Type:
Grant
Filed:
October 17, 2013
Date of Patent:
October 6, 2015
Assignee:
ChemoCentryx, Inc.
Inventors:
Manmohan Reddy Leleti, Yandong Li, Venkat Reddy Mali, Jay Powers, Ju Yang
Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, A1, A2, A3, A4, A5 and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful, for example, as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.
Type:
Grant
Filed:
November 29, 2012
Date of Patent:
September 15, 2015
Assignee:
HOFFMAN-LA ROCHE INC.
Inventors:
Johannes Aebi, Kurt Amrein, Wenming Chen, Benoit Hornsperger, Bernd Kuhn, Yongfu Liu, Hans P. Maerki, Alexander V. Mayweg, Peter Mohr, Xuefei Tan, Zhanguo Wang, Mingwei Zhou